Google
DCTH — DELCATH SYSTEMS INC (Healthcare >> Medical Devices)
DCTH FAQ
What is DCTH's P/E ratio?
DELCATH SYSTEMS INC (DCTH) currently trades at a P/E ratio of 103.07.
What is DCTH's ROE?
DELCATH SYSTEMS INC reports a Return on Equity (ROE) of 0.50%.
What is DCTH's dividend yield?
DELCATH SYSTEMS INC offers a dividend yield of 0.00%.
What is DCTH's Deepscope Quality Score?
Deepscope rates DCTH's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DCTH?
Deepscope's AI Timing Score for DCTH is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DCTH belong to?
DELCATH SYSTEMS INC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange.
|
USD 10.33
Price
-0.20
(-1.90%)
Day Change
|
|
|---|
DCTH, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
2903
|
| Magic Formula Rank by ROE |
2903
|
| Magic Formula Rank by ROIC |
1572
|
| Price | 10.33 |
| PBV / Sector |
3.23 / 7.31
|
| Earning Per Share | 0.02 |
| PE / Sector |
103.07 / 28.52
|
| PEG or PE/Growth / Sector |
-1.51 / 0.39
|
| Average 1M Daily Value |
5.67 M
GREAT
|
| Average 1W Daily Value |
5.01 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:23 |
| Symbol | DCTH |
| Name | DELCATH SYSTEMS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 34.52 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 363.51 / 17,902.07 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 566 Queensbury Avenue, Queensbury, NY, United States, 12804
Phone: 212 489 2100
Website: https://www.delcath.com
Employees: 156
Sector: Healthcare >> Medical Devices
Description: Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
